General Information of Drug (ID: DMUCQYW)

Drug Name
LMP744 Drug Info
Synonyms
LMP-744; 308246-52-8; MJ-III-65; LMP744 free base; UNII-29BY7HQV0T; NSC-706744; 29BY7HQV0T; NCI60_037977; CHEMBL126159; 308246-52-8 (free base); 6-(3-((2-hydroxyethyl)amino)propyl)-2,3-dimethoxy-5H-[1,3]dioxolo[4',5':5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione; AC1L9FIC; SCHEMBL4162998; DTXSID30327954; BCP34017; EX-A3021; BDBM50237809; HY-U00248; NSC706743; CS-7432; NSC-706743; Q27894415; 20-[3-(2-Hydroxyethylamino)propyl]-15,16-dimethoxy-5,7-dioxa-20-azapentacyclo[10.8.0.02,10.04,8.013,18]icosa-1(12),2,4(8),9,13,15,17-heptaene-11,19-dione; 5H-(1,3)Dioxolo(5,6)indeno(1,2-C)isoquinoline-5,12(6H)-dione, 6-(3-((2-hydroxyethyl)amino)propyl)-2,3-dimethoxy-; 5H-[1,6]indeno[1,2-c]isoquinoline- 5,12(6H)-dione,6-[3-[(2-hydroxyethyl)amino]propyl]-2,3-dimethoxy-; 6-[3-(2-Hydroxyethyl)aminopropyl]-5,11-diketo-2,3-dimethoxy-8,9-(methylenedioxy)- 11H-indeno[1,2-c]isoquinoline
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
PubChem CID
397888
CAS Number
CAS 308246-52-8
TTD Drug ID
DMUCQYW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting DNA topoisomerase I (TOP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [3]
Topotecan DMP6G8T Central nervous system neoplasm Approved [3]
B-Lactams DMR8YD6 Bacterial infection 1A00-1C4Z Approved [4]
Belotecan hydrocholoride DM3SRJZ Small-cell lung cancer 2C25.Y Approved [5]
Topetecan DMAE6LK Small-cell lung cancer 2C25.Y Approved [6]
Karenitecin DMCRGY4 Lung cancer 2C25.0 Phase 3 [7]
Camptothecin DM6CHNJ Solid tumour/cancer 2A00-2F9Z Phase 3 [8]
Exatecan DMCA7FN Solid tumour/cancer 2A00-2F9Z Phase 3 [9]
Edotecarin DM3ZL7D Gastric adenocarcinoma 2B72 Phase 3 [10]
Rubitecan DMDWU1S Human immunodeficiency virus infection 1C62 Phase 3 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03030417) Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas. U.S. National Institutes of Health.
2 Targeting Topoisomerase I in the Era of Precision Medicine. Clin Cancer Res. 2019 Nov 15;25(22):6581-6589.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem J. 2002 Sep 1;366(Pt 2):653-61.
5 Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43.
6 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
7 Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol.2000 Mar;57(3):453-9.
8 Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802.
9 Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 2001 Dec;7(12):3963-70.
10 Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36.
11 Rubitecan. Expert Opin Investig Drugs. 2006 Jan;15(1):71-9.